Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 19.73 USD -0.15% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Schrodinger Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Schrodinger Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
PP&E Net
$137.7m
CAGR 3-Years
17%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
PP&E Net
$116m
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
15%
Inspire Medical Systems Inc
NYSE:INSP
PP&E Net
$89.3m
CAGR 3-Years
89%
CAGR 5-Years
100%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
PP&E Net
$24.7m
CAGR 3-Years
40%
CAGR 5-Years
77%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
PP&E Net
$137.1m
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
14%
W
Waystar Holding Corp
NASDAQ:WAY
PP&E Net
$71.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry. Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.

SDGR Intrinsic Value
15 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Schrodinger Inc's PP&E Net?
PP&E Net
137.7m USD

Based on the financial report for Sep 30, 2024, Schrodinger Inc's PP&E Net amounts to 137.7m USD.

What is Schrodinger Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
46%

Over the last year, the PP&E Net growth was -3%. The average annual PP&E Net growth rates for Schrodinger Inc have been 17% over the past three years , 46% over the past five years .

Back to Top